POXEL.PA
Price:
$0.273
Market Cap:
$14.66M
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats c...[Read more]
Industry
Biotechnology
IPO Date
2015-02-06
Stock Exchange
EURONEXT
Ticker
POXEL.PA
According to Poxel S.A.’s latest financial reports and current stock price. The company's current Enterprise Value is 59.35M. This represents a change of 5.86% compared to the average of 56.07M of the last 4 quarters.
The mean historical Enterprise Value of Poxel S.A. over the last ten years is 129.55M. The current 59.35M Enterprise Value has changed 4.48% with respect to the historical average. Over the past ten years (40 quarters), POXEL.PA's Enterprise Value was at its highest in in the December 2019 quarter at 287.01M. The Enterprise Value was at its lowest in in the January 2011 quarter at 0.
Average
129.55M
Median
111.49M
Minimum
57.71M
Maximum
286.87M
Discovering the peaks and valleys of Poxel S.A. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 288.21%
Maximum Annual Enterprise Value = 286.87M
Minimum Annual Increase = -59.83%
Minimum Annual Enterprise Value = 57.71M
Year | Enterprise Value | Change |
---|---|---|
2023 | 65.96M | 14.29% |
2022 | 57.71M | -59.83% |
2021 | 143.66M | -9.36% |
2020 | 158.50M | -44.75% |
2019 | 286.87M | 288.21% |
2018 | 73.90M | -26.94% |
2017 | 101.14M | -0.98% |
2016 | 102.14M | -44.71% |
2015 | 184.72M | 52.85% |
2014 | 120.85M | -15.39% |
The current Enterprise Value of Poxel S.A. (POXEL.PA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
89.11M
5-year avg
142.54M
10-year avg
129.55M
Poxel S.A.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Poxel S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Poxel S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Poxel S.A.'s Enterprise Value?
What is the highest Enterprise Value for Poxel S.A. (POXEL.PA)?
What is the 3-year average Enterprise Value for Poxel S.A. (POXEL.PA)?
What is the 5-year average Enterprise Value for Poxel S.A. (POXEL.PA)?
How does the current Enterprise Value for Poxel S.A. (POXEL.PA) compare to its historical average?